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Experimental Procedures 
General. Unless otherwise noted, all chemicals and reagents were obtained from commercial 
suppliers (Sigma-Aldrich, VWR, Alfa Aesar) and used without further purification. Silica gel 
chromatography was carried out using AMD Silica Gel 60, 230-400 mesh. 1H and 13C NMR 
spectra were recorded on a Varian Inova 300 MHz or 500 MHz, or Bruker Prodigy 400 MHz 
instrument, in CDCl3 and are referenced to residual protio solvent signals. Data for 1H NMR are 
reported as follows: chemical shift (δ ppm), multiplicity (s = singlet, d = doublet, t = triplet, q = 
quartet, m = multiplet, dd = doublet of doublets, dt = doublet of triplets, dq = doublet of quartets, 
ddd = doublet of doublet of doublets, td = triplet of doublets), coupling constant (Hz), 
integration. Sonication was performed using a Qsonica Q500 sonicator. High-resolution mass 
spectra were obtained at the California Institute of Technology Mass Spectral Facility. Specific 
optical rotations were measured using a Jasco P-2000 Polarimeter, and are reported in units of 
deg·cm3·g–1·dm–1. Synthetic reactions were monitored using thin layer chromatography (Merck 
60 gel plates) using a UV-lamp for visualization. 
 
Chromatography. Analytical high-performance liquid chromatography (HPLC) was carried out 
using an Agilent 1200 series instrument and a Kromasil 100 C18 column (4.6 x 50 mm, 5 µm) 
with water and acetonitrile as the mobile phase. Semi-preparative HPLC was performed using an 
Agilent XDB-C18 column (9.4 x 250 mm, 5 µm) with water and acetonitrile as the mobile phase. 
Analytical chiral HPLC was conducted using a supercritical fluid chromatography (SFC) system 
with isopropanol and liquid CO2 as the mobile phase. Product enantiomers were separated using 
Chiralcel OD-H, Chiralcel OJ-H, and Chiralpak AS-H columns (4.6 x 150 mm, 5 µm) from 
Chiral Technologies Inc. 
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Cloning and site-directed mutagenesis. pET22b(+) was used as a cloning and expression 
vector for all enzymes described in this study. Site-directed mutagenesis was performed using a 
modified QuikChangeTM
 
mutagenesis protocol. The PCR products were gel purified, digested 
with DpnI, repaired using Gibson MixTM, and used to directly transform E. coli strain 
BL21(DE3).  
 
Determination of P411 concentration. The concentration of P411 enzymes in whole cell 
experiments was determined from ferrous carbon monoxide binding difference spectra using the 
previously reported extinction coefficient for serine-ligated enzymes (ε = 103,000 M–1 cm–1).1 
The concentration of purified P411 enzymes was determined by quantifying the amount of free 
hemin present using the pyridine/hemochrome assay.2 
 
Expression and amination bioconversions using whole cells. E. coli BL21(DE3) cells 
transformed with plasmid encoding P411 variants were grown overnight in 5 mL Luria-Bertani 
medium with 0.1 mg/mL
 
ampicillin (LBamp, 37 ºC, 250 rpm). The preculture was used to 
inoculate 45 mL of Hyperbroth medium (prepared from AthenaES© powder, 0.1 mg/mL
 
ampicillin) in a 125 mL Erlenmeyer flask; this culture was incubated at 37 ºC, 230 rpm for 2 h. 
Cultures were then cooled on ice (20 min) and induced with 0.5 mM IPTG and 0.5 mM 5-
aminolevulinic acid (final concentrations). Expression was conducted at room temperature, 130 
rpm, for 16 h. Cultures were then centrifuged (2,600 x g, 10 min, 4 ºC) and the pellets 
resuspended to OD600 = 30 in M9-N. Aliquots of the cell suspension (4 mL) were used to 
determine the P411 expression level after lysis by sonication. 
For amination bioconversions, the cells at OD600 = 30 in M9-N were degassed by 
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sparging with argon in sealed 6 mL crimp vials for at least 40 minutes. Separately, glucose (250 
mM in M9-N) was degassed by sparging with argon for at least five minutes. To 2 mL crimp 
vials were added an oxygen depletion system (20 µL of a stock solution containing 14,000 U/mL 
catalase and 1,000 U/mL glucose oxidase in 0.1 M KPi, pH 8.0). All solutions were uncapped 
and transferred into an anaerobic chamber. Resuspended cells (320 µL) were added to the vials, 
followed by glucose (40 µL, 250 mM in M9-N), sulfide (10 µL, 200 mM in DMSO), and tosyl 
azide (10 µL, 200 mM in DMSO). Final concentrations were 5 mM sulfide, 5 mM tosyl azide, 
and 25 mM glucose. The vials were sealed, removed from the anaerobic chamber, and shaken at 
room temperature, 40 rpm for 20 h. Reactions under aerobic conditions were performed by 
combining resuspended cells (340 µL), glucose (40 µL, 250 mM in M9-N), sulfide (10 µL, 200 
mM in DMSO), and tosyl azide (10 µL, 200 mM in DMSO) on the benchtop, without any argon 
sparging. The reactions were quenched by adding acetonitrile (450 µL) and internal standard (10 
µL of a DMSO stock). For reactions proceeding to >30% conversion (at which point the 
phenylthiosulfonamide is not completely degraded by cellular reductants), dithiothreitol was 
added (20 µL, 20 mM DTT in 0.1 M KPi, pH 8.0). This mixture was then transferred to a 
microcentrifuge tube and centrifuged at 14,000 rpm for 10 minutes. The supernatant was 
transferred to a vial and analyzed by HPLC. 
 
Reaction screening in 96-well plate format. Site-saturation libraries were generated employing 
the “22c-trick” method.3
 E. coli libraries were cultured in LBamp (300 µL/well) at 37 ºC, 220 rpm. 
Hyperbroth medium (1000 µL/well, 0.1 mg/mL
 
ampicillin) was inoculated with the preculture 
(50 µL/well) and incubated at 37 ºC, 220 rpm, 80% humidity for 3 h. The plates were cooled on 
ice for 30 minutes and then induced with 0.5 mM IPTG and 1 mM 5-aminolevulinic acid (final 
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concentrations). Expression was conducted at 20 ºC, 120 rpm for 24 h. The cells were pelleted 
(3,000 x g, 5 min, 4 ºC) and resuspended in the oxygen depletion system (20 µL/well). The 96-
well plate was then transferred to an anaerobic chamber. In the anaerobic chamber, argon-
sparged reaction buffer (50 mM glucose in M9-N, 300 µL/well) was added, followed by sulfide 
(10 µL/well, 200 mM in DMSO) and tosyl azide (10 µL/well, 200 mM in DMSO). The plate was 
sealed with an aluminum foil, removed from the anaerobic chamber, and shaken at 40 rpm. After 
16 hours, the seal was removed and acetonitrile (400 µL/well) and internal standard (10 µL/well 
of a DMSO stock) were added. The wells were mixed, the plate was centrifuged (5,000 x g, 10 
min), and the supernatant was filtered through an AcroPrep 96-well filter plate (0.2 µm) into a 
shallow-well plate for HPLC analysis.  
For the screening of site-saturation libraries for activity on sulfide 1, we used batches of 
sulfide 1 favoring the E-alkene (3:1 or 4.5:1 E:Z) for the first three libraries (at residues A268, 
L437, and S438), while for the next set of libraries (at residues A78, A82, T260, and P329) we 
performing screening using Z-1 (>15:1 Z:E). 
 
Protein purification. E. coli BL21(DE3) cells transformed with plasmid encoding P411 variants 
were grown overnight in 25 mL LBamp (37 ºC, 250 rpm). Hyperbroth medium (470 mL, 0.1 
mg/mL
 
ampicillin) in a 1 L flask was inoculated with 19 mL of the preculture and incubated at 
37 ºC, 230 rpm for 2.5 h (OD600 ca. 1.8). Cultures were then cooled on ice (30 min) and induced 
with 0.5 mM IPTG and 1 mM 5-aminolevulinic acid (final concentrations). Expression was 
conducted at room temperature, 130 rpm, for 20–24 h. Cultures were then centrifuged (5,000 x g, 
5 min, 4 ºC) and the cell pellets frozen at –20 ºC. Frozen cells were resuspended in buffer A (25 
mM tris, 20 mM imidazole, 200 mM NaCl, pH 7.5, 4 mL/g of cell wet weight), loaded with 300 
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µg/mL hemin, and lysed by sonication. To pellet insoluble material, lysates were centrifuged 
(20,000 x g, 15 min, 4 ºC). Proteins were expressed in a construct containing a 6x-His tag and 
purified using a nickel NTA column (1 mL HisTrap HP, GE Healthcare, Piscataway, NJ) using 
an AKTAxpress purifier FPLC system (GE healthcare). P411 enzymes were eluted on a linear 
gradient from 100% buffer A/0% buffer B (25 mM tris, 300 mM imidazole, 200 mM NaCl, pH 
7.5) to 100% buffer B over 10 column volumes. Fractions containing P411 enzymes were 
pooled, concentrated, and subjected to three exchanges of phosphate buffer (0.1 M KPi, pH 8.0) 
to remove excess salt and imidazole. Concentrated proteins were aliquoted, flash-frozen on 
powdered dry ice, and stored at –20 ºC. 
 
Amination bioconversions using purified protein. Purified P411 enzyme (in 0.1 M KPi, pH 
8.0, 30 µL) and the oxygen depletion system (20 µL) were added to 2 mL crimp vials. Portions 
of phosphate buffer (250 µL 0.1 M KPi, pH 8.0), glucose (40 µL, 250 mM), and NADPH (40 µL, 
100 mM), or multiples thereof, were combined in a 6 mL crimp vial and degassed by sparging 
with argon for at least 10 min. All solutions were uncapped and transferred into an anaerobic 
chamber. The buffer/reductant/glucose solution (330 µL) was added to the reaction vials, 
followed by sulfide (10 µL, 200 mM in DMSO) and tosyl azide (10 µL, 200 mM in DMSO). 
Final concentrations were typically 5 mM sulfide, 5 mM tosyl azide, 10 mM NADPH, 25 mM 
glucose, and 10 µM P411. The vials were sealed, removed from the anaerobic chamber, and 
shaken at room temperature, 40 rpm for 20 h. The reactions were quenched by adding 
acetonitrile (450 µL) and internal standard (10 µL of a DMSO stock). For reactions proceeding 
to >10% conversion, dithiothreitol was added (20 µL, 20 mM DTT in 0.1 M KPi, pH 8.0). This 
mixture was then transferred to a microcentrifuge tube and centrifuged at 14,000 rpm for 10 
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minutes. The supernatant was transferred to a vial and analyzed by HPLC. Sodium dithionite (5 
mM) was used as the reductant for reactions with hemin, myoglobin, and cytochrome c. 
Myoglobin (equine heart) and cytochrome c (bovine heart) were purchased from Sigma-Aldrich. 
 
Synthesis of substrates. 
Thioanisole and ethyl phenyl sulfide were purchased from Sigma-Aldrich and used without 
further purification. Other sulfides were synthesized according to known procedures, and their 
spectral data are in agreement with reported values.4 Tosyl azide was prepared according to de 
Nanteuil and Waser.5 
 
 
 
(Z)-But-2-en-1-yl(phenyl)sulfide (Z-1) was prepared in two steps via Lindlar hydrogenation of 2-
butyn-1-ol according to Balduzzi et al.6 followed by mesylation and displacement with 
thiophenolate according to Hiroi and Makino.7 The sulfide was obtained in 26% yield from (Z)-
2-buten-1-ol as a >15:1 Z:E mixture of alkene isomers: 1H NMR (300 MHz, CDCl3) δ 7.40–7.24 
(m, 4H), 7.22–7.14 (m, 1H), 5.87–5.47 (m, 2H), 3.58 (d, J = 6.6 Hz, 2H), 1.61–1.54 (m, 3H); 13C 
NMR (101 MHz, CDCl3) δ 136.5, 130.0, 128.9, 127.8, 126.3, 125.5, 31.0, 12.8; HRMS (FAB) 
exact mass calculated for C10H12S requires m/z 164.0660, found 164.0653. 
 
HO
Me
Lindlar
catalyst
H2, MeOH
HO
Me
1) MsCl, THF
2) PhSH, NaH, EtOH
S
Me
Ph
 7 
(Z)-Pent-2-en-1-yl(phenyl)sulfide was prepared as above from cis-2-
penten-1-ol in 15% yield, and obtained as a >15:1 Z:E mixture: 1H NMR 
(300 MHz, CDCl3) δ 7.40–7.14 (m, 5H), 5.56–5.42 (m, 2H), 3.57 (d, J = 
6.4 Hz, 2H), 2.10–1.92 (m, 2H), 0.90 (t, J = 7.5 Hz, 3H); 13C NMR (101 
MHz, CDCl3): δ 136.5, 135.4, 130.1, 128.9, 126.3, 123.9, 31.3, 20.7, 
14.2; HRMS (FAB) exact mass calculated for C11H14S requires m/z 
178.0816, found 178.0822. 
 
 (Z)-Hex-2-en-1-yl(phenyl)sulfide was prepared as above from cis-2-
hexen-1-ol in 53% yield, and obtained as a >15:1 Z:E mixture: 1H NMR 
(300 MHz, CDCl3): δ 7.39–7.32 (m, 2H), 7.31–7.23 (m, 2H), 7.22–7.14 
(m, 1H), 5.59–5.45 (m, 2H), 3.63–3.52 (m, 2H), 2.05–1.90 (m, 2H), 1.32 
(ddt, J = 14.3, 7.9, 7.0, 2H), 0.87 (t, J = 7.3 Hz, 3H); 13C NMR (101 
MHz, CDCl3): δ 136.6, 133.6, 130.0, 128.9, 126.3, 124.7, 31.4, 29.4, 
22.7, 13.9; HRMS (FAB) exact mass calculated for C12H16S requires m/z 
192.0973, found 192.0964. 
 
Characterization of reaction products. 
Authentic standards corresponding to enzymatic reaction products were prepared by tosylation of 
the corresponding allylic amine or by nitrene transfer to the corresponding sulfide according to 
the method of Okamura and Bolm.8 Phenylthiosulfonamides were cleaved to the corresponding 
sulfonamides by treatment with 0.5 M potassium hydroxide in methanol, according to Murakami 
Ph
S
Me
Ph
S
Me
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et al.9 All products are known compounds, and their spectral data are in agreement with reported 
values.9,10 
 
S-Methyl-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (11): 1H NMR 
(400 MHz, CDCl3) δ 7.77–7.67 (m, 4H), 7.57–7.45 (m, 3H), 7.20–7.14 (m, 
2 H), 2.84 (s, 3H), 2.35 (s, 3H). 
 
S-Ethyl-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (12): 1H NMR 
(300 MHz, CDCl3) δ 7.76–7.70 (m, 2H), 7.69–7.62 (m, 2H), 7.55–7.43 (m, 
3H), 7.19–7.10 (m, 2H), 3.12–2.90 (m, 2H), 2.33 (s, 3H), 1.17 (t, J = 7.3 Hz, 
3H). 
  
N-Allyl-4-methylbenzenesulfonamide (13): 1H NMR (300 MHz, CDCl3) δ 
7.75 (d, J = 8.3 Hz, 2H), 7.34–7.27 (m, 2H), 5.71 (ddt, J = 17.1, 10.2, 5.8 
Hz, 1H), 5.16 (dq, J = 17.1, 1.5 Hz, 1H), 5.08 (dq, J = 10.2, 1.4 Hz, 1H), 
4.73 (t, J = 6.2 Hz, 1H), 3.57 (tt, J = 6.0, 1.5 Hz, 2H), 2.42 (s, 3H). 
 
N-(But-3-en-2-yl)-4-methylbenzenesulfonamide (10): 1H NMR (500 MHz, 
CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.30–7.26 (m, 2H), 5.63 (ddd, J = 17.2, 
10.4, 5.8 Hz, 1H), 5.05 (ddd, J = 17.1, 1.5, 1.0 Hz, 1H), 4.96 (dt, J = 10.4, 
1.2 Hz, 1H), 4.76 (d, J = 7.7 Hz, 1H), 3.93–3.84 (m, 1H), 2.42 (s, 3H), 1.17 
(d, J = 6.8 Hz, 3H). 
 
S
MePh
N
Ts
S Me
Ph
N
Ts
NHTs
Me
HN
Ts
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N-(Pent-1-en-3-yl)-4-methylbenzenesulfonamide (14): 1H NMR (300 MHz, 
CDCl3) δ 7.74 (d, J = 8.3 Hz, 2H), 7.31–7.25 (m, 2H), 5.53 (ddd, J = 17.0, 
10.3, 6.4 Hz, 1H), 5.03–4.94 (m, 2H), 4.49 (d, J = 8.0 Hz, 1H), 3.76–3.63 
(m, 1H), 2.42 (s, 3H), 1.50 (p, J = 7.3 Hz, 2H), 0.82 (t, J = 7.4 Hz, 3H). 
 
N-(Hex-1-en-3-yl)-4-methylbenzenesulfonamide (15): 1H NMR (400 MHz, 
CDCl3) δ 7.74 (d, J = 8.3 Hz, 2H), 7.30–7.24 (m, 2H), 5.53 (ddd, J = 17.0, 
10.3, 6.6 Hz, 1H), 5.01–4.91 (m, 2H), 4.63 (d, J = 7.9 Hz, 1H), 3.80–3.70 
(m, 1H), 2.41 (s, 3H), 1.48–1.39 (m, 2H), 1.34–1.18 (m, 2H), 0.82 (t, J = 7.3 
Hz, 3H). 
 
N-(2-Methylallyl)-4-methylbenzenesulfonamide (16): 1H NMR (300 MHz, 
CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.33–7.28 (m, 2H), 4.67–4.79 (m, 2H), 
4.64 (t, J = 6.4 Hz, 1H), 3.47 (d, J = 6.5 Hz, 2H), 2.43 (s, 3H), 1.67 (s, 3H). 
 
N-(2-Methylbut-3-en-2-yl)-4-methylbenzenesulfonamide (17): 1H NMR 
(300 MHz, CDCl3) δ 7.75 (d, J = 8.3 Hz, 2H), 7.29–7.23 (m, 2H), 5.77 (dd, 
J = 17.3, 10.6 Hz, 1H), 5.08 (dd, J = 17.3, 0.7 Hz, 1H), 4.97–4.89 (m, 2H), 
2.41 (s, 3H), 1.29 (s, 6H). 
 
S-(n-Propyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (18): 1H 
NMR (300 MHz, CDCl3) δ 7.74 (d, J = 8.2 Hz, 2H), 7.70–7.65 (m, 2H), 
7.56–7.45 (m, 3H), 7.16–7.12 (m, 2H), 3.08 (ddd, J = 12.7, 8.3, 5.6 Hz, 1H), 
HN
Me
Ts
HN
Ts
Me
Me
HN
Ts
Me
Me
NHTs
Ph
S
N
Ts
Me
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2.85 (ddd, J = 12.7, 8.6, 7.1 Hz, 1H), 2.34 (s, 3H), 1.75–1.55 (m, 2H), 0.95 
(t, J = 7.4 Hz, 3H). 
 
S-(n-Butyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (19): 1H NMR 
(300 MHz, CDCl3) δ 7.77–7.64 (m, 4H), 7.55–7.44 (m, 3H), 7.18–7.12 (m, 
2H), 3.07 (ddd, J = 12.8, 8.5, 5.6 Hz, 1H), 2.87 (ddd, J = 12.7, 8.8, 7.0 Hz, 
1H), 2.34 (s, 3H), 1.70–1.43 (m, 2H), 1.42–1.20 (m, 2H), 0.82 (t, J = 7.3 Hz, 
3H). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ph
S Me
N
Ts
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Table S1. Mutations present in P450BM3 variants used in this work. 
Variant Mutations relative to wild-type P450BM3 
P411BM3-CIS T438S 
(P) 
V78A, F87V, P142S, T175I, A184V, S226R, H236Q, E252G, T268A, 
A290V, L353V, I366V, C400S, T438S, E442K 
P-I263F V78A, F87V, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268A, A290V, L353V, I366V, C400S, T438S, E442K 
P-I263F A328V V78A, F87V, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268A, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-I263F V87A V78A, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268A, A290V, L353V, I366V, C400S, T438S, E442K 
P-I263F V87A 
A328V 
V78A, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268A, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-I263F V87A 
A328V A268G 
V78A, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, I263F, 
T268G, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-I263F V87A 
A328V A268G A82L 
V78A, A82L, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
P-I263F V87A 
A328V A268G A82I 
V78A, A82I, F87A, P142S, T175I, A184V, S226R, H236Q, E252G, 
I263F, T268G, A290V, A328V, L353V, I366V, C400S, T438S, E442K 
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Table S2. Yields and enantioselectivities of whole cell bioconversions represented in Figures 1 
and 2 (and some not shown elsewhere).a 
 Thioanisole 
 
Phenyl ethyl 
sulfide 
Phenyl allyl 
sulfide 
Phenyl crotyl 
sulfide  
(3:1 E:Z) 
Phenyl crotyl 
sulfide  
(>15:1 Z:E) 
P 19% yield, 
660 TTN 
1.1% yield, 
38 TTN 
1.7% yield, 
59 TTN 
0.2% yield, 
7 TTN 
0.3% yield, 
9 TTN 
P-I263F 51% yield, 
2800 TTN 
12% yield, 
650 TTN 
3.1% yield, 
170 TTN 
0.8% yield, 
45 TTN 
1.4% yield, 
77 TTN, 
57% ee 
P-I263F 
A328V 
63% yield, 
1600 TTN 
27% yield, 
680 TTN 
9.0% yield, 
230 TTN 
4.6% yield, 
120 TTN 
10% yield, 
260 TTN, 
66% ee 
P-I263F 
V87A 
51% yield, 
4300 TTN 
43% yield, 
3600 TTN, 
48% ee 
24% yield, 
2000 TTN 
4.5% yield, 
380 TTN 
5.5% yield, 
460 TTN, 
47% ee 
P-I263F 
V87A 
A328V 
46% yield, 
1600 TTN 
54% yield, 
1800 TTN, 
82% ee 
27% yield, 
930 TTN 
6.6% yield, 
220 TTN 
14% yield, 
490 TTN, 
66% ee 
P-I263F 
V87A 
A328V 
A268G 
N.D. 75% yield, 
2500 TTN, 
39% ee 
N.D. 17% yield,  
580 TTN 
44% yield, 
1800 TTN, 
66% ee 
P-I263F 
V87A 
A328V 
A268G 
A82L 
N.D. N.D. N.D. N.D. 70% yield, 
1500 TTN,  
69% ee 
P-I263F 
V87A 
A328V 
A268G 
A82I 
N.D. 86% yield, 
2200 TTN, 
88% ee 
N.D. N.D. 77% yield, 
2200 TTN, 
68% ee 
 13 
aExperiments were performed using whole cells overexpressing the P411 variant, resuspended to 
OD600 = 30, with 5 mM sulfide and 5 mM tosyl azide. Results are the average of experiments 
performed with duplicate cell cultures, each used to perform duplicate chemical reactions (total 
of four reactions). N.D. = Not determined; ee = enantiomeric excess. 
 
Table S3. Reactions of other sulfide substrates with intermediate P411 variants. Conditions as in 
Table S2. The mutations introduced in the course of evolving a catalyst for amination of sulfide 
1 are also strongly activating toward amination of related substrates. 
 
 
 
P-I263F V87A 
A328V 
3.8% yield, 130 TTN 0.4% yield, 14 TTN 
P-I263F V87A 
A328V A268G 
18% yield, 600 TTN, 
71% ee 
7.9% yield, 260 TTN 
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Table S4. Reactions performed with purified proteins (and hemin).a 
 
catalyst percent yield, total turnovers 
hemin (25 µM) 0.2% yield, <1 TTN 
hemin (25 µM) + imidazole (1 mM) 0.2% yield, <1 TTN 
hemin (25 µM) + bovine serum albumin (10 µM) 0.1% yield, <1 TTN 
Myoglobin (equine heart) No reaction 
Cytochrome c (bovine heart) No reaction 
P411BM3 F87A T268Ab 0.6% yield, 3 TTN 
P-I263F 0.3% yield, 2 TTN 
P-I263F A328V L437Vc 1.7% yield, 9 TTN 
P-I263F V87A A328V (P-3) 10% yield, 55 TTN, 63% ee 
P-I263F V87A A328V A268G (P-4) 28% yield, 140 TTN, 63% ee 
P-I263F V87A A328V A268G A82L 63% yield, 320 TTN, 70% ee 
P-I263F V87A A328V A268G A82I (P-5, 10 µM) 52% yield, 260 TTN, 69% ee 
P-I263F V87A A328V A268G A82I (P-5, 5.0 µM) 51% yield, 510 TTN, 69% ee 
P-I263F V87A A328V A268G A82I (P-5, 2.5 µM) 43% yield, 860 TTN 
P-I263F V87A A328V A268G A82I (P-5, 1.25 µM) 19% yield, 760 TTN 
aReactions performed in duplicate, with 10 µM enzyme unless indicated otherwise; ee = 
enantiomeric excess. As in whole cells, the intermediate 8 is converted to product 9 by the 
reductant. The in vitro conditions, however, provide fewer reducing equivalents compared to the 
whole cell conditions, necessitating a DTT work-up for all reactions that proceed to >10% 
Ph
S
Me
HN
catalyst
Me
sulfide Z-1 (5 mM)
Ts
TsN3
azide (5 mM)
0.1 M KPi, pH = 8.0
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conversion. bVariant previously identified for intramolecular C–H amination.11 cVariant 
previously identified for aziridination of styrenes.12 
 
Figure S1. Location of residues subjected to site saturation mutagenesis, shown in yellow in the 
crystal structure of P-I263F; PBD: 4WG2.11 
 
 
Semi-preparative scale reactions and assignment of absolute stereochemistry. N-(But-3-en-
2-yl)-4-methylbenzenesulfonamide (10) was prepared by a semi-preparative enzymatic reaction. 
Two whole cell bioconversions were performed using 16 mL cells overexpressing variant P-5, 
resuspended to OD600 = 10 in M9-N. To the degassed cells in an anaerobic chamber were added 
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the oxygen depletion system (1.0 mL), glucose (2.0 mL, 250 mM in M9-N), sulfide Z-1 (500 µL, 
200 mM in DMSO), and tosyl azide (500 µL, 200 mM in DMSO). After 18 h, the reactions were 
diluted with 20 mL acetonitrile and 1.5 mL DTT solution (20 mM in 0.1 M KPi) and then 
centrifuged (5,000 rpm, 10 min). The supernatants were combined, extracted with EtOAc (2 x 30 
mL), and the organic layers were washed with brine (20 mL), dried over MgSO4, filtered, 
concentrated, and purified by silica gel column chromatography (eluting with 20% EtOAc in 
hexanes). The product was isolated (32.0 mg, 71% yield, 6100 TTN, 71% ee) and found to have 
[α]D25 –3.7 (c = 1.14 in CHCl3). Based on the rotations and assignments of this compound made 
by Murakami et al.9 and Moriwake et al.,13 the enzymatically produced compound is assigned as 
the (S) enantiomer. Other allylic amine products (14 and 15) were assigned by analogy. 
 
In addition, Boc-L-alanine methyl ester was derivatized according to the procedures of Moriwake 
et al.13 and Velmourougane et al.,14 providing 10 as the (S) enantiomer. The enantiopurity of the 
material was eroded to 68% ee during the reaction sequence, but the major peak matched that 
observed in the P411-catalyzed reactions, confirming assignment of the enzymatic product as the 
(S) enantiomer. 
 
S-Ethyl-S-phenyl-N-(4-methylbenzenesulfonyl) sulfimide (12) was prepared racemically and 
separated by chiral HPLC to >99% ee using a Chiralcel OJ-H column. The enantiomer formed 
preferentially by variant P-5, which elutes first on the Chiralcel OJ-H column (using 12% 
isopropanol, SFC chromatography), was found to have [α]D25 –248.2 (c = 0.38 in CHCl3). Based 
on the rotation and assignment of this compound made by Wang et al.,10a the enzymatically 
produced compound is assigned as the (S) enantiomer. 
 17 
 
S-(n-Propyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (18) was prepared by a semi-
preparative enzymatic reaction. Two whole cell bioconversions were performed using 12.8 mL 
cells overexpressing variant P-5, resuspended to OD600 = 10 in M9-N. To the degassed cells in an 
anaerobic chamber were added the oxygen depletion system (800 µL), glucose (1.6 mL, 250 mM 
in M9-N), phenyl n-propyl sulfide (400 µL, 300 mM in DMSO), and tosyl azide (400 µL, 300 
mM in DMSO). After 18 h, the reactions were diluted with 16 mL acetonitrile and centrifuged 
(5,000 rpm, 10 min). The supernatants were combined, extracted with EtOAc (2 x 30 mL), and 
the organic layers were washed with brine (20 mL), dried over MgSO4, filtered, concentrated, 
and purified by silica gel column chromatography (eluting with 50% EtOAc in hexanes). The 
product was isolated (41.2 mg, 53% yield, 6100 TTN, >99% ee) and found to have [α]D25 –277.2 
(c = 0.44 in CHCl3). Based on the rotation and assignment of this compound made by Wang et 
al.,10a the enzymatically produced compound is assigned as the (S) enantiomer. The absolute 
stereochemistry of S-(n-butyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (19) was 
assigned by analogy. 
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HPLC Calibration: Calibration curves with an internal standard were created for HPLC 
analysis of reaction products. 
 
S-Methyl-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (11), with 1.25 mM 1,3,5-trimethoxy-
benzene as internal standard, at 230 nm. 
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S-Ethyl-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (12), with 1.25 mM 1,3,5-trimethoxy-
benzene as internal standard, at 230 nm. 
	  
 
N-Allyl-4-methylbenzenesulfonamide (13), with 0.25 mM 1,3,5-trimethoxybenzene as internal 
standard, at 230 nm. 
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N-(But-3-en-2-yl)-4-methylbenzenesulfonamide (10), with 1.25 mM 4-ethylanisole as internal 
standard, at 230 nm. 
 
 
N-(Pent-1-en-3-yl)-4-methylbenzenesulfonamide (14), with 0.25 mM 1,3,5-trimethoxybenzene 
as internal standard, at 230 nm. 
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N-(Hex-1-en-3-yl)-4-methylbenzenesulfonamide (15), with 0.25 mM 1,3,5-trimethoxybenzene as 
internal standard, at 230 nm. 
 
 
N-(2-Methylallyl)-4-methylbenzenesulfonamide (16), with 1.25 mM 3-phenyl-1-propanol as 
internal standard, at 210 nm. 
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N-(2-Methylbut-3-en-2-yl)-4-methylbenzenesulfonamide (17), with 0.25 mM 1,3,5-trimethoxy-
benzene as internal standard, at 230 nm. 
 
 
S-(n-Propyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (18) with 1.25 mM 3-phenyl-1-
propanol as internal standard, at 210 nm. 
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S-(n-Butyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (19) with 1.25 mM 3-phenyl-1-
propanol as internal standard, at 210 nm. 
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HPLC co-injections of reaction mixtures with chemically synthesized authentic products. 
S-Methyl-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (11), synthetic: 
 
Enzymatic:
 
Co-injection: 
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S-Ethyl-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (12), synthetic: 
 
Enzymatic:
 
Co-injection: 
 
 
 
 
 
 
 
 
 26 
N-Allyl-4-methylbenzenesulfonamide (13), synthetic: 
 
Enzymatic: 
 
Co-injection: 
 
 
 
 
 
 
 
 
 27 
N-(But-3-en-2-yl)-4-methylbenzenesulfonamide (10), synthetic: 
 
Enzymatic: 
 
Co-injection: 
 
 
 
 
 
 
 
 
 28 
N-(Pent-1-en-3-yl)-4-methylbenzenesulfonamide (14), synthetic: 
 
Enzymatic: 
 
Co-injection: 
 
 
 
 
 
 
 
 
 29 
N-(Hex-1-en-3-yl)-4-methylbenzenesulfonamide (15), synthetic: 
 
Enzymatic: 
 
Co-injection: 
 
 
 
 
 
 
 
 
 30 
N-(2-Methylallyl)-4-methylbenzenesulfonamide (16), synthetic: 
 
Enzymatic:
 
Co-injection: 
 
 
 
 
 
 
 
 
 31 
N-(2-Methylbut-3-en-2-yl)-4-methylbenzenesulfonamide (17), synthetic: 
 
Enzymatic: 
 
Co-injection: 
 
 
 
 
 
 
 
 
 32 
S-(n-Propyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (18), synthetic: 
 
Enzymatic: 
 
Co-injection:  
 
 
 
 
 
 
 
 
 33 
S-(n-Butyl)-S-phenyl-N-(4-methylbenzenesulfonyl)sulfimide (19), synthetic: 
 
Enzymatic: 
 
Co-injection:  
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Determination of enantioselectivity. 
For chiral HPLC analysis, reaction mixtures were extracted with ethyl acetate, dried, and 
concentrated. For the sulfimidation of phenyl ethyl sulfide (6), the material was dissolved in 20% 
isopropanol in hexanes and analyzed directly by SFC for enantioselectivity. All other products 
were dissolved in acetonitrile and purified by C18 semi-preparative HPLC. The purified material 
was dried, dissolved in 20% isopropanol in hexanes, and analyzed by SFC for enantioselectivity. 
 
Enantioselectivity for enzyme-catalyzed formation of N-(but-3-en-2-yl)-4-methylbenzene 
sulfonamide (10), from the sulfide Z-1. Measured by SFC chromatography using Chiralpak 
AS-H (10% isopropanol). Racemic standard: 
 
 
 
With P-I263F (57% ee): 
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With P-I263F V87A (47% ee): 
 
 
 
With P-I263F A328V (66% ee): 
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With P-I263F V87A A328V (66% ee): 
 
 
 
With P-I263F V87A A328V A268G (66% ee): 
 
 
 
With P-I263F V87A A328V A268G A82L (69% ee): 
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With P-I263F V87A A328V A268G A82I (68% ee): 
 
 
 
Enantioselectivity for enzyme-catalyzed formation of N-(pent-1-en-3-yl)-4-methylbenzene 
sulfonamide (14). Measured by SFC chromatography using Chiralpak AS-H (20% isopropanol). 
Racemic standard: 
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With P-I263F V87A A328V A268G (71% ee):
  
 
 
With P-I263F V87A A328V A268G A82I (82% ee): 
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Enantioselectivity for enzyme-catalyzed formation of N-(hex-1-en-3-yl)-4-methylbenzene 
sulfonamide (15). Measured by SFC chromatography using Chiralpak AS-H (20% isopropanol). 
Racemic standard: 
 
 
  
With P-I263F V87A A328V A268G A82I (78% ee): 
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Enantioselectivity for enzyme-catalyzed formation of S-ethyl-S-phenyl-N-(4-methylbenzene 
sulfonyl)sulfimide (12). Measured by SFC chromatography using Chiralcel OJ-H (12% 
isopropanol). Racemic standard: 
 
 
 
With P-I263F V87A (48% ee): 
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With P-I263F V87A A328V (82% ee): 
 
 
 
With P-I263F V87A A328V A268G (39% ee): 
 
 
 
With P-I263F V87A A328V A268G A82I (88% ee): 
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Enantioselectivity for enzyme-catalyzed formation of S-(n-propyl)-S-phenyl-N-(4-
methylbenzenesulfonyl)sulfimide (18). Measured by SFC chromatography using Chiralcel OJ-
H (10% isopropanol). Racemic standard: 
 
 
 
With P-I263F V87A A328V A268G A82I (98% ee): 
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Enantioselectivity for enzyme-catalyzed formation of S-(n-butyl)-S-phenyl-N-(4-methyl 
benzenesulfonyl)sulfimide (19). Measured by SFC chromatography using Chiralcel OD-H 
(15% isopropanol). Racemic standard: 
 
 
 
With P-I263F V87A A328V A268G A82I (98% ee): 
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